CTLA4 and melanoma: Thus, blocking antibodies against CTLA4 such as ipilimumab, already approved for clinical use in melanoma patients to down regulate tumor-induced tolerance and immune suppression [37], might find a clinical application in colonic carcinogenesis [38].